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Introduction
Despite numerous advancements in the field of cancer treatment, the occurrence [1, 2] and deaths due to breast and hepatocellular carcinoma (HCC) continue to rise [1, 3] . Breast cancer and HCC account for 40,610 and 600,000 deaths in US and worldwide respectively [3] .
For decades, chemotherapy has been the mainstay treatment for both breast and liver cancer [4] . Indeed, when a patient is diagnosed with HCC at a late stage, chemotherapy becomes the only available option [5] . Doxorubicin has been identified as the most effective chemotherapeutic for many cancer types including breast cancer and HCC, despite its having many unavoidable serious side effects [6, 7] . Adverse effects mainly originate owing to high plasma levels of free doxorubicin, due to the use of high systematic doses [8] . Improved targeting is thus required.
To achieve this goal, many strategies, such as incorporation into a carrier or combining doxorubicin synergistically with another compound to reduce the toxicity, have been employed [9] . Many selective and passive delivery vehicles have been prepared using nanotechnology [9] , with the PEGylated liposomal formulation of doxorubicin (Doxil®) being the first to receive clinical approval. Doxil shows increased circulation times and more rapid uptake into tumor cells than standard doxorubicin formulations, thereby reducing the cardiotoxicity and other side effects [8, 10] .
A range of more advanced liposomal formulations such as those which are temperature sensitive, enzyme sensitive, light sensitive or functionalized with a targeting antibody [11] have also been fabricated for the purpose of doxorubicin delivery [10] . In addition, alternate systems such as copolymer micelles [12] , hydroxyapatite nanoparticles [13, 14] , hydrogels [15] and polymer-lipid hybrid nanostructures [16] have also attracted interest. In many of these instances, while the formulations reduce the toxicity exerted on normal cells their anti-cancer properties are only slightly improved [17] .
Curcumin, a well-known Asian spice is a polyphenolic compound reported to have anti-carcinogenic properties, along with many other beneficial effects [9, 18, 19] . Importantly, it is very safe as a drug, with no dose limiting toxicity [20] . The application of curcumin as an anticancer agent has been limited due to its low aqueous solubility leading to poor bioavailability, a short half-life, and rapid excretion [19, 21] . As for doxorubicin, these issues have been ameliorated in various studies via loading curcumin in polymer carriers, lipid carriers, dendrimers, liposomes, nanogels, micelles, microspheres, cyclodextrins, and inorganic nanoparticles [19, 22, 23] . Because curcumin can control and induce cell apoptosis, there may be benefits in applying it in combination therapy with chemotherapeutics like doxorubicin [24, 25] . Hydroxyapatite nanoparticles (HAp) are well known drug delivery vehicles offering high drug pay loads, pH sensitivity and controlled release of incorporated active ingredients [19, 26] . In other work, to reduce off-target effects, nanoparticles like iron oxide nanoparticles (IONPs) have been used as delivery vehicles to achieve magnetic targeting to tumor cells [18] .
A combination of HAp with IONPs could thus be beneficial because it could enhance the biocompatibility and also the drug loading ability of magnetic nanoparticles which will ultimately provide targeted delivery [19, 27] .
However, in our previous studies it has been shown that a strong interaction between HAp and IONPs could only be built up if a polysaccharide like sodium alginate (NaAlg) is used as a linker [28] . The use of magnetic HAp particles has received some attention for the treatment of cancer [21, 29, 30] . There is however no work to date on the use of HAp-NaAlg-IONP composites for the treatment of breast or liver cancer. Therefore, in this study we develop a novel drug carrier which can perform targeted, pH responsive and sustained delivery of doxorubicin, curcumin or both together to cancer cells (breast/ liver). For this purpose, hydroxyapatite was deposited on sodium alginate decorated iron oxide nanoparticles; the nanoparticles were then loaded with the respective drugs, and the resultant composite assessed for their activity on two different cancer cell lines (MCF-7 and HEpG2). anhydrous, > 99.8%), alginic acid sodium salt (NaAlg, low viscosity), cetyltrimethyl ammonium bromide (CTAB, > 98%) and Tween® 80, ammonium hydroxide solution (puriss. p.a., 25% NH 3 in H 2 O) were used as main reagents and purchased from Sigma Aldrich, India. Polyethyleneglycol 200 (PEG 200) was purchased from the Merck Millipore Corporation, Darmstadt, Germany for the preparation of surfactant coated IONPs. Snakeskin dialysis tubing (MWCO 3.5 kDa) was purchased from Thermo Fisher, India. Ultrapure deionized water was used for all the experiments.
Experimental

Materials and methods
Curcumin
Cell lines and animals
The MCF-7 breast carcinoma and HEpG2 hepatocellular carcinoma cell lines were purchased from ECACC (Salisbury, UK). MCF-7 cells were cultured in DMEM medium (Gibco, USA) containing 10% fetal bovine serum (FBS, Gibco, USA), 100 U/mL of penicillin and 100 μg/ mL of streptomycin, 1% 200 mM L-glutamine (Gibco, USA) and 1% non-essential amino acids (NEAA,100x, Gibco, USA) at 37°C in a humidified 5% CO 2 atmosphere. Similarly, HEpG2 cells were cultured in complete RPMI 1640 medium at 37°C in a humidified 5% CO 2 atmosphere. The passaging of the cell lines was carried out 2-3 times per week using 0.05% Trypsin EDTA (Gibco, USA). The African Green monkey kidney epithelial cell line Vero (ATCC, USA) was grown in complete DMEM with passage carried out in every 3-4 days using 0.05% Trypsin EDTA.
Male Wistar rats of weight 150-200 g were obtained from the rat house of the Zoology Department, University of Colombo. The animals were housed in plastic cages under standard conditions (temperature 28-31°C; approximately 12 h′ natural light per day, relative humidity 50-55%). The animals were fed with food pellets (Master Feed Ltd, Colombo, Sri Lanka) and provided with drinking water ad libitum. Animal experiments were ethically approved by the Institute of Biology of Sri Lanka (Registration No: ERC IOBSL140 02 16).
Preparation of NaAlg-hydroxyapatite-IONPs (ALG-HI)
The co-precipitation technique was followed for the synthesis of the drug carrier as reported in our previous work [28] . Polyethylene glycol (PEG) coated IONPs were synthesized using 0. 2 solution maintained at pH 8 under vigorous stirring. The pH was adjusted to 9 and a solution of (NH 4 ) 2 HPO 4 was introduced slowly to obtain ALG-HI nanocomposite [28] . The resultant black brown suspension was separated, washed and stored at 4°C until further use.
Drug loading
The loading of curcumin to ALG-HI was performed via a wet milling approach in accordance with a previous report [28] . The obtained yellow brown color suspension (CR-ALG-HI) was separated, washed and stored at 4°C until further use. For the loading of doxorubicin, 33.33 mL of a 50 ppm aqueous doxorubicin solution was added immediately to a 0.06 g/mL ALG-HI suspension and stirred at 120 rpm and at 37°C for 17 h. The doxorubicin-loaded nanoparticles were recovered via magnetic separation (DX-ALG-HI). The amount of loaded doxorubicin was calculated via fluorescence spectroscopy (Fluorolog fluorescence spectrophotometer; Horiba, Japan; λ excitation 467 nm and λ emission 589 nm) [31] . In order to load both curcumin and doxorubicin, curcumin was initially incorporated to the ALG-HI, magnetically separated, and then the nanoparticles were further incubated with the 50 ppm doxorubicin solution (yielding DX.CR-ALG-HI).
Quantification of the loaded drug content
The amount of curcumin in the NPs was determined via a simple desorption process [28] . A known amount of CR-ALG-HI was incubated with ethanol under ultrasonic irradiation. Aliquots of the released curcumin were taken periodically and replaced with an equal amount of fresh ethanol. The curcumin content in the aliquots was determined spectrophotometrically (GENESYS 10S, ThermoFisher Scientific) at 430 nm.
The doxorubicin content was measured via fluorescence spectroscopy (Fluorolog, fluorescence spectrophotometer, Horiba, Japan) by determining the amount of drug taken up from solution and using this to calculate the amount loaded in to the composite nanoparticles. Based on the loaded drug content the drug loading capacity and encapsulation efficiency [32] were determined.
Characterization of ALG-HI and the drug loaded systems
Powder X-ray diffraction (PXRD) was performed to determine the physical form of the synthesized ALG-HI. Samples were subjected to Cu Kα radiation at λ = 1.5418 Å and measurements were taken in the 2θ range 5-75 (D8 Focus X-ray diffractometer, Bruker, Germany). Fourier transform infra-red (FR-IR) spectra were recorded on a Vertex 80 instrument (Bruker, Germany). Spectra were collected over the range of 400-4000 cm −1 using KBr pellets. Scanning electron microscopy (SEM) was performed on a SU 6600 instrument (Hitachi, Japan) operating at 5.0-15 kV. Further visualization of the sample was undertaken with the use of transmission electron microscope (TEM, JEM-2010, JEOL, Japan) operating at 80 kV. Samples were also subjected to X-ray photoelectron spectroscopy (XPS) analysis with the aid of a K-alpha instrument (Thermo Scientific, East Grinsted, UK) equipped with a monochromated Al Kα X-ray source. Spectra were processed using the CasaXPS software (Casa Software Ltd., Teignmouth, UK) to identify the possible interactions of the drug molecules with the carrier ALG-HI.
In-vitro release studies
Release studies were carried out using the dialysis method, similar to the previous work by our group [28] . Briefly two PBS buffer solutions at pH 7.4 or 5.3 were prepared and supplemented with 1% (w/w) of Tween 80. A known amount of the drug-loaded nanoparticles were placed in a dialysis bag (MWCO of 3500) and immersed in the buffer solutions (20 mL) under gentle stirring at 37°C. At specific time intervals, 0.5 mL of the solution was withdrawn and replenished with an equal volume of fresh preheated buffer. These aliquots removed were analyzed for curcumin and doxorubicin as detailed above. The release study was continued until the solution drug concentration reached an equilibrium. All experiments were carried out in triplicate. The following equation (Eq. (1)) was used to determine the cumulative drug release percentage [33] .
In-vitro cytotoxicity assessment
The in vitro cytotoxicity of the formulations against MCF-7 and HEpG2 cells was determined with the WST-1 cell viability determination assay [34] . Cells were seeded in 96-well plates (CELLSTAR®, Greiner, Germany) at a density of 3 × 10 3 cells/well and incubated overnight [21, 35] in the appropriate media under standard cell culture conditions. They were subsequently treated with a series of different concentrations of the nanoparticles and/or drug loaded nanoparticles dispersed in complete media for 24, 48 and 72 h before the cell viability was quantified [36] using WST-1 solution (Abcam, UK). The detailed protocol is given in the Supplementary Information.
Cellular uptake studies
Cells were first cultured in 8-well chamber slides (Nunc® Lab-Tek® Chamber Slide™, Thermo Fisher, USA) and treated with IC50 concentrations of nanoparticles for 24, 48 and 72 h. All experiments were performed in triplicate. After each incubation the cells were washed with cold PBS, and fixed with 3.7% paraformaldehyde in PBS (VWR, UK) for 15 min at room temperature. The fixed cells were washed and treated with 100 µg/mL AO/EB (Thermo Fisher Scientific, Life Technologies, Singapore) solution for 10 min in the dark [37] . Similarly, for Hoechst staining the fixed cells were washed with 0.1% Triton X in PBS followed by the addition of 5 µg/mL Hoechst reagent (Thermo Fisher Scientific, Life Technologies, Singapore) in 0.1% Triton X/PBS and incubated for 15 min at room temperature in the dark. After each incubation the stained cells were washed with PBS and a coverslip placed on the slide using a permanent mounting medium [38] . Finally, the samples were visualized under a fluorescence microscope (FSX 100, Olympus, Japan).
Flow cytometry
Apoptosis was quantified by flow cytometry using the Annexin V APC (Biolegend USA; cat number-640920) and Zombie green (ZGBiolegend, USA; cat number -423111) double staining protocol [39] . MCF or HEpG2 cells/well were grown in 24 well plates overnight under standard cell culture conditions. On the following day the cells were incubated with the IC50 values of each nanoparticle system for another 18 h. After the incubation they were washed, trypsinized, detached, stained and analyzed by flow cytometry. Media alone was used as the negative control. To avoid spectral overlap, single stains of cells with Annexin V and cells with ZG were used as compensation controls. The signals from Annexin V and ZG were acquired (Guava easyCyte 12 HT instrument, Merck, Germany equipped with blue (488 nm), red (642 nm) and violet (405 nm) lasers and the data were analyzed with FCS Express version 4 (Denovo Software, USA). All experiments were undertaken in triplicated.
Hemolysis assay
Hemolysis (rupture of red blood cells-RBCs) was also used as a measure of cytotoxicity evaluation for the nanomaterials [21] . Briefly, rat blood collected into EDTA was centrifuged, rinsed and diluted in PBS. 100 µL aliquots of the diluted red blood cells were added to 900 µl of a test solution containing different concentrations (0.01-160.0 µg/ mL) of the nanoparticles. The samples were next incubated for 2 h with gentle shaking. RBCs incubated with deionized water and PBS were used as the positive and the negative controls, respectively. After incubation the samples were centrifuged and the absorbance of the supernatant measured at 541 nm using a UV-visible spectrophotometer (GENESYS 10S, Thermo Scientific, India). All samples were tested in triplicate. The following equation was used to obtain the percentage of hemolysis (Eq. 
where A sample is the absorbance of the blood of the test sample, A negative control is the absorbance of the blood with PBS and A positive control is the absorbance of the blood with water.
Effect of the formulations on rat bone marrow cells
Myelosuppression is the single most important factor that determines toxicity in the treatment of cancer [40] . A detailed description for obtaining rat bone marrow cells is given in the Supplementary Information. After several washing steps with RPMI, the primary bone marrow cells obtained from sacrificed rats in complete RPMI were seeded at a density of 1-9 × 10 4 cells/ well in 96 well plates, and incubated for 3 h under standard cell culture conditions. These cells were then treated with a series of different concentration of nanoparticles for 24 h [41] . Thereafter, cell viability was assessed via the MTT assay protocol [42] . All samples were tested in triplicate in three individual experiments.
Effect of the formulations on non-cancerous Vero cells
In addition to the effect on cancerous cells, the effect of the bare nanoparticles and drug loaded nanoparticles on the non-cancerous epithelial Vero cell lines was also assessed [43] . The cells were seeded in 96 well plates and incubated for overnight under standard cell culture conditions. On the following day they were treated with a series of different concentrations of nanoparticles and incubated 24 h before cell viability was assessed via the WST-1 cell viability assessment assay as specified in Section 2.8.
Statistical analysis
Data are presented as mean ± SEM. One-way analysis (ANOVA) of variance was used to determine statistical significance of the cumulative release rate and cell viability followed by Tukey-Kramer post-hoc test. P-values < 0.05 were considered statistically significant. All statistical analyses were performed using SPSS version 19 (IBM Corporation, USA).
Results and discussion
Synthesis and characterization of drug-loaded nanoparticles
The neat ALG-HI drug carrier was characterized using XRD, FT-IR and SEM analysis and the successful synthesis of ALG-HI was confirmed (see data given in Supplementary Information Fig. S1, Fig. S2 and Fig.  S3 ) in accordance with our previous report [28] . Fig. 1 displays the FT-IR spectra of the drug-loaded formulations.  Fig. 1a is the spectra of neat ALG-HI which is compared with the drug loaded systems. In neat curcumin (Fig. 1b) , the appearance of a sharp band at 3511 cm −1 and a broader peak at 3373 cm −1 can be attributed to aliphatic eOH groups and phenol eOH groups respectively [19, 35, 44] . When curcumin molecules interacted with the ALG-HI (CR-ALG-HI) (Fig. 1c) , there is a clear broadening and reduction in intensity of the eOH stretching bands [45] . The appearance of eCH 2 stretching bands of CTAB [46] at 2925 cm −1 and 2856 cm −1 have masked the CH stretch of eOeCH 3 in curcumin, which would be expected to appear at 2946 cm −1 [44] . However, the 1374 cm −1 and 816 cm −1 vibrational bands of neat curcumin (CH deformation of eCH 3 groups and alkene bends) [45] have shifted to 1395 cm −1 and 818 cm −1 in the curcumin loaded nanoparticles providing evidence of the interaction of curcumin with the nanoparticles. The FT-IR spectra of both neat doxorubicin and DX-ALG-HI are given in Fig. 1d and e. Similar observation on the band shifting can be made for DX-ALG-HI (Fig. 1e) . The eOH stretching band of doxorubicin [47] is visible at 3371 cm −1 in DX-ALG-HI , shifted from its position in the neat drug carrier nanoparticle (3141 cm
). The presence of bands at 1584 cm −1 and 1616 cm −1 for neat doxorubicin (Fig. 1d) can be attributed to the stretching of its two carbonyl groups [21] . The appearance of an intense band at 1616 cm −1 further confirmed the incorporation of doxorubicin molecules in to the nanoparticles of DX-ALG-HI. Moreover, a weak band at 1287 cm −1 in the doxorubicin loaded nanoparticle system corresponds to the eCeOeCe stretching vibration of doxorubicin [48] . When both curcumin and doxorubicin were co-loaded into the ALG-HI (DX. CR-ALG-HI) (Fig. 1f) , the IR spectrum appears very similar to that of CR-ALG-HI. However, the presence and interaction of both drug molecules with the ALG-HI in DX.CR-ALG-HI was confirmed by XPS (See Supplementary Information, Tables S1-S4 and Fig. S3-S7 ). The XPS data clearly indicated that when the drug molecules are loaded into the carrier there are shifts in the position of the peaks corresponding to Ca, Fe, P, N, C and O atoms, indicative of drug/carrier interactions.
Morphological observations were obtained by SEM and TEM images which are given in Fig. 2 . It is clear that the nanoparticles are aggregated, and discrete particles are hard to distinguish in the SEM images. TEM data show the average size of the neat carrier to be about 13-17 nm. The sizes of CR-ALG-HI, DX-ALG-HI and DX.CR-ALG-HI are larger at 23.4 ± 5.1 nm, 20.6 ± 3.4 nm and 34 ± 5.2 nm respectively. In all the systems, the obtained nanoparticles are well below 50 nm, suggesting they will have the ability to be internalized into cells and progress to the nucleus via the enhanced permeation and retention (EPR) effect [49] .
Assessment of drug loading capacity and encapsulation efficiency
The drug loading capacities (DL) and the encapsulation efficiencies (EE) are given in Table S5 . It could be seen that these systems have different values for those two parameters and both DL% and EE% of the co-loaded system are lower than the individual drug loaded systems.
Drug release
The drug release profiles are given in Fig. 3 . The neat drug showed a burst of release within a very short time independent of pH. However, the release of drugs from the ALG-HI drug carrier showed a dependency on pH (greater release at lower pH). In the release patterns of both drugs from their carriers, there was an initial burst release within the first 5-6 h which was then followed by sustained release over a period of 168 h. Such a burst release can be attributed to the release of surface adsorbed drug molecules [9] . The subsequent slow release can be attributed to favorable interactions between the drug molecules and carrier through electrostatics, van der Waals forces and hydrogen bonding [28] .
The drug release from each system is tabulated in Table S6 . However, in both cases it could be seen that the released drug content is higher in singly loaded system than their co-loaded systems.
With respect to curcumin, the doxorubicin cumulative release amount is significantly lower (P < 0.05), which could be due to the favorable interactions that are formed between the negatively charged centers of ALG-HI and the positively charged doxorubicin ions or van der Waals interactions between the polysaccharide units in the carrier and the doxorubicin [50] .
The advantage of the drug delivery system prepared in this work are thus clear; it is capable of performing sustained and pH sensitive drug release. This may be facilitated by the "open-close gate mechanism mediated by CTAB molecules [28] and the gradual dissolution of the HAp coating material [51] . The system is particularly promising for the treatment of cancer as the drugs are more rapidly released at a lower pH, typical of the cancer micoenvironment [28] .
In-vitro cytotoxicity
The dose response and time response curves for the two cell lines are given in Fig. 4, Fig. 5, Fig. S8 and Fig. S9 . It is clearly observed that the drug loaded ALG-HI particles have much more profound time controlled cell disruption ability than the neat drug molecules. This is expected to be due to the extended release of drug molecules from the nanocarrier, in contrast to the rapid release seen with the neat drugs. By such a mechanism, the formulations maintain a prolonged anti-proliferative effect which could minimize the requirement for repeated dosages.
Similarly, when considering the IC50 values of each formulation (Table S7) to MCF-7 breast cancer cells and HEpG2 hepatocellular carcinoma cells, it is clearly evidenced that these values are much lower than the IC50 values of curcumin and doxorubicin alone. The CR-ALG-HI system has significantly lower IC50 values (P < 0.05) than the neat drug at all three time points. Furthermore, compared with the literature, the IC50 value found here for CR-ALG-HI is remarkably low highlighting its potency against both cell types [22, 52, 53] .
A similar trend is observed with DX-ALG-HI, again with very low IC50 values. These values are promising when compared to the reported work [54, 55] . Compared to the CR-ALG-HI and DX-ALG-HI the combined DX.CR-ALG-HI system is no more effective with MCF-7 cells than the single-drug systems. However, with respect to neat curcumin and doxorubicin, the IC50 values of the co-loaded system are much lower. More importantly our systems have much lower IC50 values than have been reported in the literature for curcumin/doxorubicin combined treatment of breast and liver cancer [9, 22, 25] . With the HEpG2 cells the co-loaded system performs even better than the single-drug analogue or the neat drugs, resulting in lower IC50 values. This could be due to the synergistic effect [4] created by curcumin molecules over the activity of doxorubicin. The increase in glutathione (GSH) levels is generally a key factor leading to resistance in chemotherapy or radiotherapy [56] . However, it has been found that HEpG2 cells have very high levels of intrinsic GSH [56] requiring higher IC50 dosages. Therefore, the co-delivery of both curcumin and doxorubicin via this drug carrier might have permitted a reduction of GSH levels and thereby requiring low IC50 to provide the effect. Fig. 6, Fig. 7 and Figs. S10-S12 depict phase contrast images and fluorescence images of cells that have been treated with the nanoparticles for 24, 48 and 72-hours. It is clearly visible that the control cells have maintained the fusiform shape while being uniformly stained in green (AO/EB staining) and blue (Hoechst staining), showing them to be healthy [57] . However, as shown in Fig. 6a, b and Fig. S10 , when both MCF-7 cells and HEpG2 cells are treated by curcumin, they have started to undergo apoptosis, expressing bright yellow to orange nuclei European Journal of Pharmaceutics and Biopharmaceutics 128 (2018) [18] [19] [20] [21] [22] [23] [24] [25] [26] with AO/EB staining and medium to bright blue color with Hoechst staining. Further, the cells have shrunk and appear to have irregular shapes [58] . The cell number reduces with time, as cells have undergone death and been removed with the washing steps. This effect is much more profound with the CR-ALG-HI treated systems which has led to the appearance of more round shaped cells and bright nuclei due to the chromatin condensation and nuclear fragmentation [58] . Most of the cells have lost cell integrity and have not stained well with Hoechst [57] . Similar observations can be made with doxorubicin and the doxorubicin loaded nanoparticles, as given in Fig. 7 and Figs. S11, S12. More specifically it is obvious that the apoptotic effect is much stronger with these systems than with curcumin, confirming the potency of doxorubicin and its lower IC50 values. The dual drug loaded materials (Fig. S13a, b) are much effective against HEpG2 cells than MCF-7 cells, as was noted previously.
Fluorescence imaging
Flow cytometry
The results of staining to quantify live/apoptotic/late apoptotic and dead cells are given in Fig. 8 and Fig. S14 . These reveal that, compared to the neat drug molecules, drug loaded ALG-HI formulations show a higher percentage of cells lying in the late apoptotic and necrotic or dead stages. This is common to all the NP systems. Compared to HEpG2 cells, apoptotic induction in MCF-7 is greater. MCF-7 cells have apoptotic or dead cells at 23.95 ± 0.89%, 42.56 ± 0.34% and 39.05 ± 0.45% when incubated with CR-ALG-HI, DX-ALG-HI and DX.CR-ALG-HI respectively. Similarly, in HEpG2 cells a significantly greater percentage (P < 0.05) of cells undergoing apoptosis and necrosis could be seen with cells treated with CR-ALG-HI, DX-ALG-HI and DX.CR-ALG-HI materials (67.01 ± 0.55%, 21.62 ± 0.67%, 49.55 ± 0.35%) with respect to the control and the neat drug treatment. This has further highlighted that the apoptotic induction ability of these systems is far superior than the neat drug doxorubicin and therefore they could be used as a replacement for the toxic doxorubicin.
In general, this remarkable apoptosis induction ability of the drug loaded nanoparticles could arise due to greater uptake of the nanoparticles (cf. the neat drugs) and the diffusion of more drug molecules into the nucleus [59, 60] . The histograms of single stains (cells stained with Annexin V or ZG separately) used as compensation controls are given in Fig. S15. 3.7. Assessment of hemocompatibility, bone marrow proliferation and effect on non-cancerous cells
As shown in Fig. S16 , low hemolytic percentages well below 1.5%, suggest the hemocompatibility of the nanoparticles. These values are very low compared with the reported work on these drugs and similar drug loaded nanoparticles [19, 61] . All the drug loaded nanoparticles are critically safe to be used for cancer treatment, as recommended by ISO/TR 7406 [61] .
The effect of curcumin, doxorubicin, and the CR-ALG-HI, DX-ALG-HI and DX.CR-ALG-HI formulations on the cell proliferation of rat bone marrow cells (Fig. S17) reveal that both the ALG-HI nanoparticles and the drug loaded ALG-HI systems led to a very high viability even at high concentrations. Thus, the drug loaded nanoparticle systems do not induce adverse effects on bone marrow cells, demonstrating their excellent biocompatibility. This might arise due to the inherent biocompatibility properties of the ALG-HI components (HAp, NaAlg and IONPs) [42] .
From the cytotoxicity results on non-cancerous Vero cells (depicted in Fig. S18a-c) , it is clear that there are differences in how cancerous and non-cancerous cells respond to the formulations. The viability of the Vero cells is generally high, with the NPs performing significantly better than the free drug in this regard. Given that the IC50 values obtained for the drug loaded nanoparticles against MCF-7 and HEpG2 cells are very much lower compared to the reported work it appears that these formulations are much safer for therapeutic use than the pure drugs. The cytotoxic effects caused by our nanoparticles on Vero cells are very low when compared with the reported work carried out using carbon nanotubes (CNTs) and Al 2 O 3 nanoparticles [62, 63] .
Conclusions
A drug carrier comprised of a magnetic core with a hydroxyapatite (HAp) shell was successfully synthesized and loaded with curcumin, doxorubicin and a combination of the two in this work. Efficient loading was observed, and the release of the drugs was pH sensitive, with faster release in the mildly acidic conditions typical of the cancer microenvironment. Extended release over around one week was observed. Anti-proliferative studies have proven that the curcumin, doxorubicin, and dual drug loaded nanoparticles are very potent, with lower IC50 values against breast and liver cancer cells than the free drug molecules. Fluorescence imaging and flow cytometry reveals that this is due to the greater extent of apoptosis induced by the drug loaded nanoparticles. Hemolysis tests, cytotoxic evaluation on bone marrow cells and green monkey kidney epithelial cells verified that the nanoparticle systems are devoid of adverse side effects, and cause selective toxicity to cancer cells while leaving healthy cells unaffected. The drug loaded nanoparticles reported here could potentially minimize the amount of doxorubicin or curcumin required for effective therapeutic action, ensuring the minimization of any possible side effects. Society for the award of an International Exchanges Grant (IE161184) to RMdeS, KMNdeS and GRW.
